Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients

Reporting results of cancer treatment

A. B. Miller, Barth Hoogstraten, M. Staquet et al. · Cancer · 1981 · 7.9K citations

Pharmacy, Oncology, Clinical Data Management +16

The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump.

G J Zaman, M J Flens, Manuel R. van Leusden et al. · Proceedings of the National Academy of Sciences · 1994 · 692 citations · Full text

Medicine, Oncology, Pharmacology +17

Kinetics of pharmacologic response I. Proposed relationships between response and drug concentration in the intact animal and man

John G. Wagner · Journal of Theoretical Biology · 1968 · 305 citations

Medicine, Pharmacokinetics, Pharmacology +13

Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines.

Abdul M. Deffie, Janendra K. Batra, Gerald J. Goldenberg · PubMed · 1989 · 263 citations

Medicine, Molecular Biology, Oncology +14

Adriamycin cardiomyopathy—risk factors

Robert A. Minow, Robert S. Benjamin, Elisa T. Lee et al. · Cancer · 1977 · 253 citations · Full text

Medicine, Cardiology, Pharmacology +17